Navigation Links
Cobalis Reports Phase III Trial Results for PreHistin in Seasonal,Allergic Rhinitis

ck the symptom-causing effects of histamine may be eliminated, or minimized. PreHistin is patented for the treatment of atopic allergic diseases such as seasonal and perennial allergies, dermatitis, migraine, food allergies and asthma.

About Cobalis Corp.

Cobalis Corp. is a specialty pharmaceutical development company specializing in medications to prevent and treat atopic disease, including allergies, migraine headache, atopic asthma and dermatitis. Its flagship drug candidate PreHistin is an allergy medication in Phase III clinical development. For further information, visit www.cobalis.com

Safe Harbor Statement: This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cobalis disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, any statements relating to the timing, scope or expected outcome of the Company's clinical development of its drug candidates, the potential benefits of the Company's drug candidates and the size of the potential market for the Company's products. Such statements are based on management's current expectations, but actual results may differ materially due to various factors. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to securing funding for ongoing operations including clinical trials, difficulties or delays in development, testing, regulatory approval, production and marketing of the Company's drug candidates, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug candidates that could slow or prevent product approval or market acceptance (including the risk that current and past results of clinical trials are not necessarily indicative of future resu
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cobalis Expects to Report Phase III Top-Line Results in May
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:12/4/2009)... Inc. (NYSE Amex: PIP ), a biodefense company ... today the presentation of new data from the Company,s ... Antigen (rPA) based anthrax vaccine is structurally stable and ... and including 55 degrees C. The data were ...
(Date:12/4/2009)... 4 Hospira, Inc. (NYSE: HSP ), ... today announced the launch of its next-generation 50 mL ... and solutions, and now offers a complete size range ... responsible VisIV product. The launch of the 50 mL ...
(Date:12/4/2009)... PharmAthene, Inc. (NYSE Amex: PIP ), ... and chemical threats, announced today that the Company ... effectiveness of Valortim® in an inhalation anthrax model ... The data are being presented during an oral ...
Breaking Medicine Technology:PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 2PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 3PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 4PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 5Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 2Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 3Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 4PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 3PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 4PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 6AMICAS PACS For Mammography at RSNA 2009 61273 1AMICAS PACS For Mammography at RSNA 2009 61273 2AMICAS PACS For Mammography at RSNA 2009 61273 3Reportlinker Adds Diclofenac sodium 28CAS 15307 79 6 29 Market Research Report 2009 14821 1Reportlinker Adds Diclofenac sodium 28CAS 15307 79 6 29 Market Research Report 2009 14821 2Reportlinker Adds US Orthopedic Devices Market Analysis 26amp 3B Forecasts to 2015 6234 1Reportlinker Adds US Orthopedic Devices Market Analysis 26amp 3B Forecasts to 2015 6234 2Reportlinker Adds US Orthopedic Devices Market Analysis 26amp 3B Forecasts to 2015 6234 3Reportlinker Adds US Orthopedic Devices Market Analysis 26amp 3B Forecasts to 2015 6234 4Reportlinker Adds US Orthopedic Devices Market Analysis 26amp 3B Forecasts to 2015 6234 5Reportlinker Adds US Orthopedic Devices Market Analysis 26amp 3B Forecasts to 2015 6234 6Reportlinker Adds US Orthopedic Devices Market Analysis 26amp 3B Forecasts to 2015 6234 7Reportlinker Adds US Orthopedic Devices Market Analysis 26amp 3B Forecasts to 2015 6234 8Reportlinker Adds US Orthopedic Devices Market Analysis 26amp 3B Forecasts to 2015 6234 9Reportlinker Adds US Orthopedic Devices Market Analysis 26amp 3B Forecasts to 2015 6234 10Reportlinker Adds US Orthopedic Devices Market Analysis 26amp 3B Forecasts to 2015 6234 11Reportlinker Adds US Orthopedic Devices Market Analysis 26amp 3B Forecasts to 2015 6234 12Reportlinker Adds US Orthopedic Devices Market Analysis 26amp 3B Forecasts to 2015 6234 13Reportlinker Adds US Orthopedic Devices Market Analysis 26amp 3B Forecasts to 2015 6234 14Reportlinker Adds US Orthopedic Devices Market Analysis 26amp 3B Forecasts to 2015 6234 15Reportlinker Adds US Orthopedic Devices Market Analysis 26amp 3B Forecasts to 2015 6234 16Reportlinker Adds US Orthopedic Devices Market Analysis 26amp 3B Forecasts to 2015 6234 17
(Date:12/6/2009)... Hamilton, ON. Dec. 6, 2009 A new study ... disorder known as venous thromboembolism (VTE). , The ... Americans every year, and occurs when an abnormal clot ... blood, causing pain and swelling. In some cases, the ... travel through the heart to the lungs, causing a ...
(Date:12/6/2009)... organizations and members of the community, in cooperation with the Greater ... a holiday party. This year,s attendance is expected to soar to ... , ... (PRWEB) December 6, 2009 -- Volunteer ... VA Healthcare System in West Los Angeles, will once again create ...
(Date:12/5/2009)... three-drug combination has shown in a phase 1/2 ... in the treatment of patients newly diagnosed with multiple ... marrow, say researchers from Dana-Farber Cancer Institute. , Partial ... 66 patients treated with the drug combination in the ... partial response rate" in the phase 2 population, reports ...
(Date:12/5/2009)... WASHINGTON, Dec. 5 ,, What: Cuts ... a difference in the fight against cancer and other terminal ... will be donated to St. Jude Children,s Research Hospital. Guests ... Sisters, a delectable and savory Vietnamese restaurant in Falls Church ...
(Date:12/5/2009)... Cancer Is Most Challenging-- ,, PHILADELPHIA and ... specific genes, dubbed partner genes, that fuse with another ... infants. By more accurately defining specific partner genes, researchers ... particular treatments. ,, Oncologists also aim to use ...
Breaking Medicine News(10 mins):Health News:New drug shows promise for those with clotting disorders: McMaster researcher 2Health News:17th Annual Event Honoring 5,000 + Veterans, Military Personnel to Include Real Life “Heroes” 2Health News:17th Annual Event Honoring 5,000 + Veterans, Military Personnel to Include Real Life “Heroes” 3Health News:Multiple myeloma patients experience high response rate with new 3-drug combination 2Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 2Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 3Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 4
... to 2.2 million additional cases in U.S. by 2050 , , ... dehydration linked to global warming will boost kidney stone rates ... suggests. , In the United States in particular, hotter weather ... among residents of southern states -- the so-called "kidney-stone belt." ...
... food diary program to aid in weight loss efforts is offered ... ... July 14 Recognizing the,importance of educating consumers about the nutritional ... site at, http://www.sunkistdailydiet.com to provide users with a free, easy-to-use,always ...
... Ancillary Group ... Benefits -, PHILADELPHIA, ... LNC ) today announced it,will move to a new and expanded Dental ... October 1, 2008. The,Lincoln DentalConnect(SM) plan, provides access to more than 52,000 ...
... and 50 local students, WHAT: To help celebrate the kick off of the ... will conduct a fitness clinic to encourage ... drinking milk, Four lucky students ... Josh Boone,s week long basketball camp., WHY: With the ...
... to the brain, heparin more risky, study finds , , MONDAY, ... heparin is associated with an increased risk of serious bleeding ... shows. , But another thinning agent, warfarin, did not ... of patients. , This finding led the authors of a ...
... Study found those who were more fit had larger ... and women with early-stage Alzheimer,s disease who were more ... counterparts in less stellar shape. , The findings, though ... the brain atrophy (shrinkage) associated with Alzheimer,s disease. Or ...
Other Medicine News:Health News:Global Warming Linked to Heightened Kidney Stone Risk 2Health News:Global Warming Linked to Heightened Kidney Stone Risk 3Health News:Use of Food Diary Helps Increase Weightloss 2Health News:Lincoln Financial Group Announces New Dental Panel of Providers 2Health News:Lincoln Financial Group Announces New Dental Panel of Providers 3Health News:Warfarin Safer Than Heparin for Some Strokes 2Health News:Exercise Might Slow Brain Shrinkage in Alzheimer's Patients 2Health News:Exercise Might Slow Brain Shrinkage in Alzheimer's Patients 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: